The FDA’s Pharmacy Compounding Advisory Committee voted narrowly in favour of adding six peptides to the agency’s 503A Bulks List at its July 23-24 meeting.
The six peptides recommended for inclusion are BPC-157, KPV, TB-500, MOTs-C, Semax and Epitalon, following divergent views among committee members during the two-day session.
One peptide, Emideltide, also known as DSIP, failed to secure support from the advisory committee and was not recommended for addition to the list.
The committee vote is advisory only and does not automatically change the legal status of any of the peptides under discussion or create an immediate safe harbour for compounding.
Formal revision of the 503A Bulks List requires the FDA to complete a rulemaking process, which involves issuing a proposed rule for public comment before any final rule can take effect.
That rulemaking process can take years, meaning the PCAC vote alone does nothing to resolve the current regulatory ambiguity surrounding these peptide compounds in the near term.
Despite the absence of immediate legal change, the outcome is expected to increase pressure on the FDA to ease existing compounding restrictions for the six recommended peptides.
The FDA could choose to exercise enforcement discretion, issuing guidance to signal it does not intend to take regulatory action against pharmacies that compound using some or all of the discussed peptides.
Any such enforcement discretion policy would likely include conditions around sourcing, testing and documentation that the FDA would expect compounders to satisfy before relying on it.
Compounders and other stakeholders should pay close attention to which peptides are covered by any new guidance, whether it applies to 503B outsourcing facilities, and whether limits on routes of administration are imposed.
Telehealth platforms exploring a launch of compounded peptide products must consider whether they will adequately disclose continued regulatory ambiguity to members and ensure providers retain independent clinical decision-making authority.
Med spas, wellness centres and other providers interested in offering compounded peptides must assess sourcing, prescribing arrangements, patient consent practices and compliance with state advertising laws.
All stakeholders should implement a review process for websites, paid influencer content, social media and other marketing materials before publication, given recent regulatory scrutiny of direct-to-consumer advertising in this space.
State pharmacy boards and professional regulators are not required to align with any FDA guidance, making it essential for businesses to monitor state-level developments alongside any federal policy changes.
The PCAC meeting increases the likelihood of future policy changes, but those changes are not guaranteed and could arrive with significant limitations that affect commercial and clinical planning.